{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:41:43Z","timestamp":1789018903873,"version":"build-2803163510"},"reference-count":55,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health (NIH)","award":["R01CA196266"],"award-info":[{"award-number":["R01CA196266"]}]},{"name":"National Institutes of Health (NIH)","award":["R01CA196266-01A1:S1"],"award-info":[{"award-number":["R01CA196266-01A1:S1"]}]},{"name":"National Institutes of Health (NIH)","award":["R01CA196266-03"],"award-info":[{"award-number":["R01CA196266-03"]}]},{"name":"National Institutes of Health (NIH)","award":["R01CA253215"],"award-info":[{"award-number":["R01CA253215"]}]},{"name":"National Institutes of Health (NIH)","award":["P30AI028697"],"award-info":[{"award-number":["P30AI028697"]}]},{"name":"UCLA Jonsson Comprehensive Cancer Center","award":["R01CA196266"],"award-info":[{"award-number":["R01CA196266"]}]},{"name":"UCLA Jonsson Comprehensive Cancer Center","award":["R01CA196266-01A1:S1"],"award-info":[{"award-number":["R01CA196266-01A1:S1"]}]},{"name":"UCLA Jonsson Comprehensive Cancer Center","award":["R01CA196266-03"],"award-info":[{"award-number":["R01CA196266-03"]}]},{"name":"UCLA Jonsson Comprehensive Cancer Center","award":["R01CA253215"],"award-info":[{"award-number":["R01CA253215"]}]},{"name":"UCLA Jonsson Comprehensive Cancer Center","award":["P30AI028697"],"award-info":[{"award-number":["P30AI028697"]}]},{"name":"UCLA AIDS Institute and UCLA Center for AIDS Research NIH","award":["R01CA196266"],"award-info":[{"award-number":["R01CA196266"]}]},{"name":"UCLA AIDS Institute and UCLA Center for AIDS Research NIH","award":["R01CA196266-01A1:S1"],"award-info":[{"award-number":["R01CA196266-01A1:S1"]}]},{"name":"UCLA AIDS Institute and UCLA Center for AIDS Research NIH","award":["R01CA196266-03"],"award-info":[{"award-number":["R01CA196266-03"]}]},{"name":"UCLA AIDS Institute and UCLA Center for AIDS Research NIH","award":["R01CA253215"],"award-info":[{"award-number":["R01CA253215"]}]},{"name":"UCLA AIDS Institute and UCLA Center for AIDS Research NIH","award":["P30AI028697"],"award-info":[{"award-number":["P30AI028697"]}]},{"name":"James B. Pendleton Charitable Trust and the McCarthy Family Foundation","award":["R01CA196266"],"award-info":[{"award-number":["R01CA196266"]}]},{"name":"James B. Pendleton Charitable Trust and the McCarthy Family Foundation","award":["R01CA196266-01A1:S1"],"award-info":[{"award-number":["R01CA196266-01A1:S1"]}]},{"name":"James B. Pendleton Charitable Trust and the McCarthy Family Foundation","award":["R01CA196266-03"],"award-info":[{"award-number":["R01CA196266-03"]}]},{"name":"James B. Pendleton Charitable Trust and the McCarthy Family Foundation","award":["R01CA253215"],"award-info":[{"award-number":["R01CA253215"]}]},{"name":"James B. Pendleton Charitable Trust and the McCarthy Family Foundation","award":["P30AI028697"],"award-info":[{"award-number":["P30AI028697"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Transferrin receptor 1 (TfR1), also known as CD71, is a transmembrane protein involved in the cellular uptake of iron and the regulation of cell growth. This receptor is expressed at low levels on a variety of normal cells, but is upregulated on cells with a high rate of proliferation, including malignant cells and activated immune cells. Infection with the human immunodeficiency virus (HIV) leads to the chronic activation of B cells, resulting in high expression of TfR1, B-cell dysfunction, and ultimately the development of acquired immunodeficiency syndrome-related B-cell non-Hodgkin lymphoma (AIDS-NHL). Importantly, TfR1 expression is correlated with the stage and prognosis of NHL. Thus, it is a meaningful target for antibody-based NHL therapy. We previously developed a mouse\/human chimeric IgG3 specific for TfR1 (ch128.1\/IgG3) and showed that this antibody exhibits antitumor activity in an in vivo model of AIDS-NHL using NOD-SCID mice challenged intraperitoneally with 2F7 human Burkitt lymphoma (BL) cells that harbor the Epstein-Barr virus (EBV). We have also developed an IgG1 version of ch128.1 that shows significant antitumor activity in SCID-Beige mouse models of disseminated multiple myeloma, another B-cell malignancy. Here, we aim to explore the utility of ch128.1\/IgG1 and its humanized version (hu128.1) in mouse models of AIDS-NHL. To accomplish this goal, we used the 2F7 cell line variant 2F7-BR44, which is more aggressive than the parental cell line and forms metastases in the brain of mice after systemic (intravenous) administration. We also used the human BL cell line JB, which in contrast to 2F7, is EBV-negative, allowing us to study both EBV-infected and non-infected NHL tumors. Treatment with ch128.1\/IgG1 or hu128.1 of SCID-Beige mice challenged locally (subcutaneously) with 2F7-BR44 or JB cells results in significant antitumor activity against different stages of disease. Treatment of mice challenged systemically (intravenously) with either 2F7-BR44 or JB cells also showed significant antitumor activity, including long-term survival. Taken together, our results suggest that targeting TfR1 with antibodies, such as ch128.1\/IgG1 or hu128.1, has potential as an effective therapy for AIDS-NHL.<\/jats:p>","DOI":"10.3390\/cancers15061816","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T02:29:59Z","timestamp":1679020199000},"page":"1816","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8277-9702","authenticated-orcid":false,"given":"Tracy R.","family":"Daniels-Wells","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre V.","family":"Candelaria","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Kranz","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"},{"name":"UCLA AIDS Institute, Los Angeles, CA 90095, USA"},{"name":"Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"},{"name":"UCLA AIDS Institute, Los Angeles, CA 90095, USA"},{"name":"UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"},{"name":"UCLA AIDS Institute, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-3742","authenticated-orcid":false,"given":"Masakazu","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Heersink School of Medicine, University of Alabama, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Almagro","sequence":"additional","affiliation":[{"name":"GlobalBio, Inc., Cambridge, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoniel","family":"Mart\u00ednez-Maza","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"},{"name":"UCLA AIDS Institute, Los Angeles, CA 90095, USA"},{"name":"UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA"},{"name":"Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"},{"name":"Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel L.","family":"Penichet","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"},{"name":"Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"},{"name":"UCLA AIDS Institute, Los Angeles, CA 90095, USA"},{"name":"UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA"},{"name":"The Molecular Biology Institute, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1749-6632.1984.tb37161.x","article-title":"High-grade non-Hodgkin\u2019s lymphoma in patients with AIDS","volume":"437","author":"Ziegler","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/PPO.0000000000000448","article-title":"HIV Lymphoma and Burkitts Lymphoma","volume":"26","author":"Noy","year":"2020","journal-title":"Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","article-title":"Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: A population-based study","volume":"28","author":"Gibson","year":"2014","journal-title":"AIDS"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1002\/cncr.25530","article-title":"Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007","volume":"116","author":"Seaberg","year":"2010","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3018(20)30118-1","article-title":"Epidemiology of haematological malignancies in people living with HIV","volume":"7","author":"Kimani","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_6","unstructured":"Centers for Disease Control (1985). Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States. MMWR Morb. Mortal Wkly. Rep., 34, 373\u2013375."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/01.cco.0000432525.70099.a4","article-title":"Pathology of lymphoma in HIV","volume":"25","author":"Cesarman","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_8","first-page":"439","article-title":"AIDS-related cancers in the era of highly active antiretroviral therapy","volume":"15","author":"Biggar","year":"2001","journal-title":"Oncology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2352-3026(20)30126-5","article-title":"HIV-associated Burkitt lymphoma","volume":"7","author":"Murphy","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/QAD.0000000000002498","article-title":"Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan","volume":"34","author":"Nishijima","year":"2020","journal-title":"AIDS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1086\/499054","article-title":"Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France","volume":"42","author":"Bonnet","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12026-010-8168-8","article-title":"HIV-associated immune dysfunction and viral infection: Role in the pathogenesis of AIDS-related lymphoma","volume":"48","author":"Epeldegui","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/QAI.0b013e31829d4d50","article-title":"TLR2 activated B cells are phenotypically similar to the abnormal circulating B cells seen preceding the diagnosis of AIDS related non-Hodgkin lymphoma (NHL) diagnosis","volume":"64","author":"Guo","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.path.2019.03.005","article-title":"Human Immunodeficiency Virus-Associated Lymphoproliferative Disorders","volume":"12","author":"Lilly","year":"2019","journal-title":"Surg. Pathol. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.4049\/jimmunol.138.11.3720","article-title":"Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity","volume":"138","author":"Crabb","year":"1987","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"607692","DOI":"10.3389\/fimmu.2021.607692","article-title":"Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents","volume":"12","author":"Candelaria","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Essaghir, A., and Demoulin, J.B. (2012). A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039666"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Maguire, A., Chen, X., Wisner, L., Malasi, S., Ramsower, C., Kendrick, S., Barrett, M.T., Glinsmann-Gibson, B., McGrath, M., and Rimsza, L.M. (2019, January 21\u201322). Potential Alternative Survival Mechanisms in HIV-Associated Diffuse Large B-Cell Lymphoma (DLBCL) of Germinal Center (GCB) Origin. Proceedings of the 17th International Confereence on Malignancies in HIV\/AIDS, Bethesda, MD, USA.","DOI":"10.1002\/hon.12_2630"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2019-129346","article-title":"Over-Expression of Transferrin Receptor (TFRC\/CD71) and Low Expression of Innate and Adaptive Immune Cell Subsets in HIV-Associated, GCB-DLBCL By Digital Gene Expression Profiling","volume":"134","author":"Maguire","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2007.08.020","article-title":"Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor","volume":"124","author":"Rodriguez","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2006-04-020263","article-title":"Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor","volume":"108","author":"Ng","year":"2006","journal-title":"Blood"},{"key":"ref_22","first-page":"6295","article-title":"Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects","volume":"50","author":"White","year":"1990","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318222ffc8","article-title":"An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies","volume":"34","author":"Daniels","year":"2011","journal-title":"J. Immunother"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.4049\/jimmunol.1700787","article-title":"Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma","volume":"200","author":"Leoh","year":"2018","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000092","article-title":"Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma","volume":"38","author":"Widney","year":"2015","journal-title":"J. Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/CJI.0000000000000304","article-title":"An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication","volume":"43","author":"Candelaria","year":"2020","journal-title":"J. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr Virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/nm1197-1242","article-title":"HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas","volume":"3","author":"Moses","year":"1997","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41551-019-0434-z","article-title":"Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice","volume":"3","author":"Wen","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_30","unstructured":"Penichet, M.L., Daniels-Wells, T.R., Candelaria, P.V., and Almagro, J.C. (2020). Compositions and Methods for Transferrin Receptor 1 Targeting. (No. PCT\/US2020\/059532), International Patent Application, Publication Number: WO\/2021\/092482A1, Publication Date: 14 May 2021."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.173.4.1025","article-title":"The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain","volume":"173","author":"Tao","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_32","first-page":"65","article-title":"Growth rate analysis and efficient experimental design for tumor xenograft studies","volume":"13","author":"Hather","year":"2014","journal-title":"Cancer Inform."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/1535-7163.MCT-21-0074","article-title":"Targeting TfR1 with the ch128.1\/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV(+) Human Primary B-cells","volume":"20","author":"Martinez","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1128\/JVI.06397-11","article-title":"An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses","volume":"86","author":"Helguera","year":"2012","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0959-8049(01)00119-8","article-title":"Genetic pathways and histogenetic models of AIDS-related lymphomas","volume":"37","author":"Carbone","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjh.13998","article-title":"Central nervous system involvement in AIDS-related lymphomas","volume":"173","author":"Barta","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_37","unstructured":"Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius, J., Schmidlin, K., Costagliola, D., Fatkenheuer, G., May, M., Caro Murillo, A.M., Mocroft, A., Bonnet, F., and Clifford, G. (2009). Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS, 23, 2029\u20132037."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.123.5.2168","article-title":"The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function","volume":"123","author":"Roder","year":"1979","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4049\/jimmunol.123.5.2174","article-title":"The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect","volume":"123","author":"Roder","year":"1979","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/infdis\/171.6.1664","article-title":"Defective killing of Candida albicans hyphae by neutrophils from beige mice","volume":"171","author":"Balish","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.molimm.2015.07.001","article-title":"Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1","volume":"67","author":"Leoh","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41467-021-27949-3","article-title":"Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections","volume":"13","author":"Hickerson","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Richard, C., and Verdier, F. (2020). Transferrin Receptors in Erythropoiesis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249713"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sakamoto, S., Kawabata, H., Masuda, T., Uchiyama, T., Mizumoto, C., Ohmori, K., Koeffler, H.P., Kadowaki, N., and Takaori-Kondo, A. (2015). H-Ferritin Is Preferentially Incorporated by Human Erythroid Cells through Transferrin Receptor 1 in a Threshold-Dependent Manner. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0139915"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41467-019-09098-w","article-title":"Cryo-EM structure of the human ferritin-transferrin receptor 1 complex","volume":"10","author":"Montemiglio","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_47","unstructured":"(2022, December 06). Phase I, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous PPMX-T003 in Polycythemia Vera (Identifier: NCT05074550), Available online: ClinicalTrials.gov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2017.02.039","article-title":"Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia\/lymphoma","volume":"485","author":"Shimosaki","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1538-7445.AM2017-5586","article-title":"PPMX-T003, a fully human anti-TfR1 antibody with potent efficacy against hematologic malignancies [abstract]","volume":"77","author":"Zhang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ogama, Y., Kumagai, Y., Komatsu, N., Araki, M., Masubuchi, N., Akiyoshi, H., Matsuura, T., Kirisako, H., Kyoya, A., and Nomura, F. (2022). Phase 1 Clinical Trial of PPMX-T003, a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate Its Safety, Pharmacokinetics, and Pharmacodynamics. Clin. Pharmacol. Drug Dev., Online ahead of print.","DOI":"10.1002\/cpdd.1216"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1084\/jem.175.6.1501","article-title":"Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow","volume":"175","author":"Lansdorp","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1634\/stemcells.2007-0117","article-title":"Phenotypic and Functional Reversal Within the Early Human Hematopoietic Compartment","volume":"26","author":"Valerio","year":"2008","journal-title":"Stem Cells"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0609.1997.tb01693.x","article-title":"Characterization and phenotypic analysis of differentiating CD34+ human bone marrow cells in liquid culture","volume":"59","author":"Gross","year":"1997","journal-title":"Eur. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tiv.2012.10.006","article-title":"Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1","volume":"27","author":"Helguera","year":"2013","journal-title":"Toxicol. Vitr."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1816\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:57:16Z","timestamp":1760122636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["cancers15061816"],"URL":"https:\/\/doi.org\/10.3390\/cancers15061816","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]}}}